Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS)

NCT ID: NCT05263557

Last Updated: 2023-07-25

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-19
• Study Completion Date: 2024-12-31

Brief Summary

Androgen excess is the cardinal biochemical feature of polycystic ovary syndrome (PCOS). Serum testosterone correlates with insulin resistance in PCOS, however, there is an urgent need to improve our understanding of the association between androgens and the risk of type 2 diabetes.

11-oxygenated steroids are the predominant androgens in PCOS and correlate closely with markers of insulin resistance. The bioactive 11-oxygenated androgen 11-ketotestosterone (11KT) binds and activates the androgen receptor with equal affinity to testosterone, yet nothing is known about its impact on metabolism or glucose homeostasis

Crucially, there are no data linking androgen excess with muscle glucose metabolism and the differential contribution of 11-oxygenated androgens to diabetes risk through these processes remains unknown.

The investigators hypothesise the following:

1. Oral androgen exposure in women with PCOS results in distinct changes in tissue-specific insulin sensitivity and muscle energy biogenesis

2. 11-oxygenated androgen exposure exerts differential changes on the above parameters in comparison to classic androgen exposure

The study has the following aims:

1. To examine the impact of oral androgen exposure on skeletal muscle insulin sensitivity and glucose disposal in women with PCOS.

2. To delineate the impact of androgen exposure on muscle mitochondrial function ex vivo in women with PCOS

3. To compare the differential impact of 11-oxygenated androgen compared to classic androgens on glucose disposal and muscle mitochondrial function

The two arms will run in parallel and all participants will undergo identical investigations before and after 7 days of either DHEA or 11KA4.

Investigations will include baseline arthrometric measurements muscle biopsy, two-step hyperinsulinaemic euglycaemic clamp, breath sampling.

This interventional metabolic phenotyping study will probe the role of classic and 11-oxygenated androgens in metabolic dysfunction in PCOS using gold-standard in vivo metabolic phenotyping techniques. Delineating the distinct contribution of 11-oxygenated androgens, through effects on skeletal muscle biology, to the risk of T2DM is an important step in the process of determining risk of type 2 diabetes in this vulnerable cohort.

Conditions

Polycystic Ovary Syndrome; Insulin Resistance; Androgen; Hypersecretion; Endocrine System Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

DHEA

Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.

Group Type: EXPERIMENTAL

Dehydroepiandrosterone (DHEA)

Intervention Type: DIETARY_SUPPLEMENT

Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.

11KA4

Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.

Group Type: EXPERIMENTAL

11-ketoandrostenedione (11KA4)

Intervention Type: DIETARY_SUPPLEMENT

11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.

Interventions

Dehydroepiandrosterone (DHEA)

Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.

Intervention Type: DIETARY_SUPPLEMENT

11-ketoandrostenedione (11KA4)

11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Women with a confirmed diagnosis polycystic ovary syndrome with androgen excess on clinical or biochemical grounds
• BMI 20.0-39.9kg/m2
• Age range 18-40 years
• Ability to provide informed consent

Exclusion Criteria

• A confirmed diagnosis of diabetes
• Current or recent (<3-months) use of weight loss medications
• Current or recent use of oral contraceptive pill or hormone replacement therapy (within 3-months)
• Blood haemoglobin <12.0g/dL
• History of alcoholism or a greater than recommended alcohol intake (recommendations > 21 units on average per week for men and > 14 units on average per week for women)
• Haemorrhagic disorders or Treatment with anticoagulant agents
• Any medical condition in the opinion of the investigator that might impact upon safety or validity of the results
• Pregnancy or breastfeeding at the time of planned recruitment
• A diagnosis of PCOS according to Rotterdam criteria where the patient does not have clinical or biochemical evidence of androgen excess
• History of significant renal (eGFR<30) or hepatic impairment (AST or ALT >two-fold above ULN; pre-existing bilirubinaemia >1.2 ULN)
• Any other significant disease or disorder that, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
• Current intake of drugs known to impact upon steroid or metabolic function or intake of such drugs during the six months preceding the planned recruitment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Oxford

OTHER

Sponsor Role: collaborator

University of Birmingham

OTHER

Sponsor Role: collaborator

Royal College of Surgeons, Ireland

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael W Michael

Role: PRINCIPAL_INVESTIGATOR

RCSI Education & Research Centre, Beaumont Hospital, Beaumont Dublin 9 Ireland Ireland

Locations

Beaumont Hospital

Dublin, , Ireland

Site Status: RECRUITING

Countries

Ireland

Central Contacts

Michael W O'Reilly

Role: CONTACT

michaelworeilly@rcsi.ie

018093894

Facility Contacts

Michael O'Reilly

Role: primary

michaelworeilly@rcsi.ie

018093894

Other Identifiers

DIMOXIS

Identifier Type: -

Identifier Source: org_study_id